ClinicalTrials.gg
Sign In
TerminatedNCT00052039Updated Nov 6, 2007

A Randomized, Double-Blind, Three-Arm, Phase 3b Study Comparing the Safety and Efficacy of Interferon Gamma-1b With Azathioprine, and Azathioprine Alone in Patients With IPF Receiving Prednisone

A Phase 3 interventional study of interferon-gamma 1b and azathioprine in Lung Disease and Pulmonary Fibrosis, sponsored by InterMune. Terminated at 1 site in Italy. Open to participants aged 20 Years to 79 Years. Per ClinicalTrials.gov, last updated 2007-11-06.

Primary conditionIdiopathic Pulmonary FibrosisRegistry: Lung DiseasesReclassifiedWhy we changed it
Registry
Lung Diseases — the first condition term the registry derived for this study.
ClinicalTrials.gg
Idiopathic Pulmonary Fibrosis
Why
  1. The study's title name Idiopathic Pulmonary Fibrosis, a narrower term within Lung Diseases.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by InterMune (part of Hoffmann-La Roche) · Phase 3, Interventional, and Treatment

Why this study was terminated
Study design changes were needed based on GIPF-001 results
Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
20 Years to 79 Years
Sex
All
01

Study summary

Study GIPF-003 is a Phase 3b study designed to define better therapeutic use of IFN-gamma 1b in patients wtih IPF. The study will be conducted primarily in Europe and will enroll 210 patients.

02

Conditions studied

  • Lung Disease
  • Pulmonary Fibrosis

Browse trials for

Keywords

  • idiopathic pulmonary fibrosis
03

In context

Idiopathic Pulmonary Fibrosis Reclassified

576 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 123 are open to participants now.

Browse Idiopathic Pulmonary Fibrosis studies →

Lead sponsor

InterMune is the lead sponsor of 15 studies on the registry; none are open to participants now.

First submitted before InterMune became part of Hoffmann-La Roche.

Browse InterMune studies →All Hoffmann-La Roche studies →

Compared within Idiopathic Pulmonary Fibrosis, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lung Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
20 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No
This record does not list eligibility criteria. Contact the study team before assuming you do or do not qualify.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
0 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. This study was terminated prior to enrollment.

    Time frame: This study was terminated prior to enrollment.

07

Study locations

1 site
  • Ospedale S. Luigi Gonzaga - Regione
    Torino, Orbassano 10043, Italy
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 6, 2007, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00052039
Lead sponsor
InterMune
First posted
Jan 22, 2003
Start date
Apr 2002
Completion
Jun 2002
Last update
Nov 6, 2007

Study contacts

Steven Porter, MD
study director · InterMune
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2007. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Interferon gamma-1b · Azathioprine

Other studies in this condition

Idiopathic Pulmonary Fibrosis →

Other studies from this sponsor

InterMune →

Start the discussion